Trailing-twelve-month (TTM) revenue is $25.84 Billion with a year-over-year growth of +8.48%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $6,057,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-31 |
| Q4 FY2025Period ended 2025-12-31 | $7,171,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-11 |
| Q1 FY2026Period ended 2026-03-31 | $6,020,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-11 |
| Q2 FY2026Period ended 2026-06-30 | $6,589,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-31 |
| TTM revenue | $25,837,000,000 |
Current P/S: $107,916,054,503 market capitalization ÷ $25,837,000,000 TTM revenue = 4.18x.
Market capitalization source: FMP quote. Quote observed 2026-09-15T20:00:02.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $6.59B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-15T22:21:04.065Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| MedSurg | $6.4B | $9.5B | $10.6B | $11.8B | $13.5B | $15.6B |
| Orthopaedics | $5.0B | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Asia Pacific | $1.6B | $2.0B | $1.9B | $1.9B | $2.0B | $2.2B |
| EMEA | $1.8B | $2.3B | $2.3B | $2.6B |
$25.84B
$25.84 Billion
+8.48%
vs. $23.82B a year ago (TTM)
+9.72%
5 Year compound annual growth rate
1 Year
+8.48%
3 Year
+9.92%
5 Year
+9.72%
10 Year
+9.45%
15 Year
+8.29%
20 Year
+8.45%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $25.12B | +$2.52B | +11.16% |
| 2024 | $22.59B | +$2.10B | +10.23% |
| 2023 | $20.50B | +$2.05B | +11.11% |
| 2022 | $18.45B | +$1.34B | +7.84% |
| 2021 | $17.11B | +$2.76B | +19.21% |
| 2020 |
TTM Growth
+8.48%
3-Year CAGR
+9.92%
5-Year CAGR
+9.72%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-15T22:21:04.065Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $9.1B |
| $9.5B |
| Orthopaedics and Spine | $3.0B | $7.6B | $7.8B | $8.7B | N/A | N/A |
|---|
| $3.2B |
| Other foreign countries | $448M | $515M | $578M | $677M | $735M | $765M |
|---|
| United States | $10.5B | $12.3B | $13.6B | $15.3B | $16.9B | N/A |
|---|
| $14.35B |
| ($533.00M) |
| (3.58%) |
| 2019 | $14.88B | +$1.28B | +9.43% |
| 2018 | $13.60B | +$1.16B | +9.30% |
| 2017 | $12.44B | +$1.12B | +9.88% |
| 2016 | $11.32B | +$1.38B | +13.86% |
